نبذة مختصرة : Bu tezin, veri tabanı üzerinden yayınlanma izni bulunmamaktadır.Yayınlanma izni olmayan tezlerin basılı kopyalarına üniversite kütüphaneniz aracılığı ile (TÃœBESS üzerinden) eriÅŸebilirsiniz. ; Ä°ntimal hyperplasia which is noticed in endarterectomy, balloon angioplasty, stent implantation and vascular bypass grafts anastomosis is one the biggest factors in making percutaneous revakularizasyon insufficient. Depending on pathophysiological features of neointimal hyperplasis various pharmacological agent is used. Cilostazol is one of these drugs. We also study we aimed to show the inhibitory effect of cilostazol on neointimal hyperplasia,For this, the right carotid artery intimal injury created with embolectomy catheter of 20 rats, group 1 (sham group), group 2 (control group) and group 3 (experimental group) were divided into 3 groups. Cilostazol for 14 days was given orally at a dose of 20 mg / kg. At the end of 14 days from the rat carotid preparations were evaluated pathologically and histochemically. Working with materials as a result of the increase in intimal thickness and intimal thickening in terms of parameters beyond the rate of thickening of the medial-10.1 program using SSPI: Kruskalwalls analysis of variance test, Mann-Whitney test, Bonferroni sensitivity, significance of the difference between the two paired test, paired two-sample Wilcoxon signed rank tests, and statistical analysis was.Ä°ntimal thickening : Group 1 and Group 2 , Group 2 and Group 3 showed significant difference. Ratio between intimal thickening and medial thickening: There isn?t my significant difference between group 1 and group 3. However, significant difference is found between Group 1 - Group 2 and Group 2- Group 3. This case shows that endotel damage is limited by cilostazol and neointimal hyperplasis is decreased. This case is interpreted positively towards intimal hiperplasis. The difference between Group 2 and Group 3 show that inhibitory effect of cilostazol on intimal hyperplasia. There is no significant ...
No Comments.